BACKGROUND

Cyclic AMP–dependent protein kinase A (PKA) and protein phosphatase 1 (PP1) are multifunctional proteins involved in numerous essential signalling pathways that modulate physiological and pathological functions which have been implicated in cancer development and progression. Both PKA and PP1 are oligomeric enzymes composed of catalytic and regulatory subunits. PKA is a heterotetramer of two catalytic (encoded by PRKACA, PRKACB, PRKACG) and two regulatory (encoded by PRKAR1A, PRKAR1B, PRKAR2A, PRKAR2B) subunits. PKA is involved in a wide array of cellular processes, including metabolism, gene expression and apoptosis. PKA is also expected to play a variety of roles dictated by cellular context due to its influence of multiple cellular signalling pathways. Interestingly, in breast cancer, PKA is capable of phosphorylating serine 305 of oestrogen receptor α (ERα) to induce tamoxifen resistance and alter the transcriptome through redirection of ERα to new transcriptional start sites.1,2 Low PRKAR1A/high SRC mRNA has been shown to
define basal-like and HER2-positive breast cancers with a worse clinical outcome,
and PKA activity has also been implicated in HER2 resistance in vitro, in particular down-regulation of the PKA-R1α subunit.

Like PKA, PP1 is a multifunctional protein involved in a large array of important cellular pathways. PP1 is an oligomeric enzyme that contains one catalytic subunit (encoded by PPP1CA, PPP1CB and PPP1CC) and at least one regulatory subunit (16 regulatory subunits). Importantly, PP1 plays a role in mitotic regulation, glycosylation metabolism and RNA splicing. In cancer, PP1 has been shown to play a role in the tumour microenvironment and in steering cellular migration, and it has been shown to interact with BRCA1.

Both PP1 and PKA can be inhibited by dopamine- and cAMP-regulated phosphoprotein 32 kD (DARPP-32), also known as protein phosphatase one regulatory subunit 1B and encoded by PPP1R1B. DARPP-32 was originally described as a signalling protein highly concentrated in regions of the brain enriched in dopaminergic nerve terminals. DARPP-32 is able to inhibit both PKA and PP1 dependent upon its phosphorylation status. For instance, DARPP-32 is phosphorylated on threonine 34 by PKA to allow it to act as a potent inhibitor of PKA. Cyclin-dependent kinase (Cdk)-5 can phosphorylate DARPP-32 on threonine 75 to allow it to act as a PKA inhibitor. In a variety of cancers, a truncated DARPP-32 splice variant (t-DARPP) is expressed; importantly, this isoform lacks the ability to inhibit PKA, but retains PKA inhibitory activity. Phosphorylation of t-DARPP has been shown to mediate PKA activation, which appears to be via association between t-DARPP and the regulatory R1 subunit.

There is accumulating evidence that differential expression of DARPP-32 and t-DARPP is functionally significant in numerous tumour types (reviewed in). Low levels of DARPP-32 protein expression are associated with shorter cancer-specific survival of breast and ovarian cancer patients. In trastuzumab-resistant breast cancer cells, t-DARPP activated IGF-1R signalling, which stimulated glycolysis and conferred trastuzumab resistance. In gastric cancer, DARPP-32 is frequently overexpressed in the early stages of gastric cancer. In lung cancer, DARPP-32 and t-DARPP promoted tumour cell growth in vivo and in vitro. In pancreatic cancer, loss of HIF1α increased PPP1R1B expression, and DARPP-32 promoted degradation of p53 through phosphorylation of MDM2.

DARPP-32 is phosphorylated by PKA or Cdk5 to alter its inhibitory activity; Cdk5 is involved in neuronal maturation but is also implicated in cancer and neurodegenerative disorders. In breast cancer, low Cdk5 expression has also been shown to be associated with adverse survival of breast cancer patients.

In breast cancer, we hypothesize that a reduction in DARPP-32 and an increase in t-DARPP in breast cancer result in a concomitant alteration of PKA and PP1 signalling. We sought to determine the expression of PKA and PP-1 mRNA and protein in a large cohort of early-stage invasive breast cancer patients to understand their relationship between survival and clinicopathological criteria and to determine their relationship between DARPP-32 and Cdk5 expression.

## 2 | METHODS

### 2.1 | Patient cohorts

Breast cancer patients were all treated at Nottingham University Hospitals between 1998 and 2006. Patients underwent a wide local excision or mastectomy, decided by disease characteristics or patient choice, followed by radiotherapy if indicated. Nottingham Prognostic Index (NPI), ER and menopausal status determined if patients received systemic adjuvant treatment. Patients with an NPI score less than 3.4 did not receive adjuvant treatment, and patients with an NPI score of 3.4 and above were candidates for CMF combination chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil) if they were ER-negative or pre-menopausal; and hormonal therapy if they were ER-positive.

PKA mRNA expression and PP-1 mRNA expression were determined in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) data set (n = 1980), and DNA and RNA were isolated from samples and hybridized to the Affymetrix SNP 6.0 and Illumina HT-12 v3 platforms for genomic and transcriptional profiling as described by Curtis et al. Tumours were collected by five centres in the UK and Canada between 1977 and 2005, and almost all ER-negative and lymph node–positive patients received adjuvant chemotherapy, whereas ER-positive and/or lymph node–positive patient did not. No patients with HER2 overexpression received trastuzumab.

### 2.2 | Immunohistochemistry

Immunohistochemistry was performed on tissue microarrays comprised of single 0.6 mm cores taken from a representative tumour area as assessed on haematoxylin and eosin–stained sections by a specialist breast cancer histopathologist. Immunohistochemical staining was achieved using a Novolink Polymer Detection Kit (Leica) according to the manufacturers' instructions, the use of which has been described previously. Briefly, tissue was deparaffinized in xylene and rehydrated in ethanol followed by water. Antigen retrieval was performed in 0.01 mol L⁻¹ sodium citrate buffer (pH 6.0), with tissue heated for 10 minutes at 750 W in a microwave and then 10 minutes at 450 W. Tissue was blocked with Novolink Peroxidase Block and then Novolink Protein Block solution with Tris-buffered saline (TBS) washes in-between. Rabbit polyclonal PKA C-α antibody (Cell Signalling Technology #4782) was used at a concentration of 1:50 diluted in Bond Primary Antibody Diluent (Leica). Mouse monoclonal PP-1 alpha antibody (clone 10C6-3, Life technologies) was used at concentration of 1:100 diluted in Bond Primary Antibody Diluent (Leica). Both antibodies were incubated on tissue for 1 hour at room temperature, and antibody specificity was confirmed by Western blotting using breast cancer cell lysates prior to use. Following antibody incubation, tissue was washed with TBS before application of Novolink Post Primary solution, further TBS washes and Novolink Polymer
solution. Immunohistochemical reactions were developed using 3,3′-diaminobenzidine as the chromogenic substrate and tissue were counterstained with haematoxylin. Tissue was dehydrated in ethanol and fixed in xylene prior to mounting using DPX. Breast tumour composite sections comprising of grade 1 and 2 early-stage invasive tumours were used as positive and negative controls, and were included with each staining run.

2.3 | Scoring and statistical analysis

Slides were scanned at 200× magnification using a Nanozoomer Digital Pathology Scanner (Hamamatsu Photonics). Cytoplasmic staining was assessed using a semi-quantitative immunohistochemical H-score, where staining intensity within tumour cells was assessed as none (0), weak (1), medium (2) or strong (3) over the percentage area of each staining intensity. Nuclear staining was assessed as the percentage of tumour cells that demonstrated any staining intensity. Greater than 30% of cores for each TMA were double assessed, with both assessors blinded to clinical outcome and each other’s scores.

Statistical analysis was performed using IBM SPSS Statistics (version 24). X-tile was used to determine cut-points for assessment using breast cancer–specific survival. Single measure intraclass correlation coefficients were used to determine concordance between scorers with levels above 0.7 that indicated good concordance. The Pearson chi-squared test of association was used to determine the relationship between categorized protein expression and clinicopathological variables. Survival curves were plotted according to the Kaplan-Meier method with significance determined using the log-rank test. Multivariate survival analysis was computed using the Cox regression analysis. All differences were deemed statistically significant at the level of $P \leq .05$. This study is reported according to REMARK criteria. Broad Institute Morpheus software was used to visualize data (https://software.broadinstitute.org/morpheus). Expression of PKA and PP1 was
|                  | PKA cytoplasmic | PP-1 cytoplasmic | PP-1 nuclear |
|------------------|-----------------|-----------------|--------------|
|                  | Low | High | P value | Low | High | P value | Low | High | P value |
| **Patient age** |     |      |         |     |      |         |     |      |         |
| <50 y            | 41  | 328  | 0.919   | 428 | 71   | 0.140   | 428 | 71   | 0.043   |
| ≥50 y            | 84  | 695  | 0.734   | 1019| 134  | 0.140   | 1032| 124  | 0.043   |
| **Tumour size** |     |      |         |     |      |         |     |      |         |
| <2CM             | 71  | 617  | 0.499   | 891 | 135  | 0.242   | 902 | 127  | 0.371   |
| ≥2CM             | 54  | 406  | 0.354   | 555 | 70   | 0.420   | 557 | 68   | 0.410   |
| **Tumour grade**|     |      |         |     |      |         |     |      |         |
| 1                | 21  | 144  | 0.501   | 231 | 30   | 0.245   | 229 | 32   | 0.838   |
| 2                | 50  | 384  | 0.334   | 599 | 75   | 0.458   | 601 | 76   | 0.460   |
| 3                | 54  | 495  | 0.431   | 616 | 100  | 0.617   | 629 | 87   | 0.536   |
| **Tubule formation** |   |      |         |     |      |         |     |      |         |
| 1                | 12  | 69   | 0.257   | 104 | 15   | 0.473   | 103 | 16   | 0.855   |
| 2                | 29  | 297  | 0.261   | 418 | 67   | 0.418   | 429 | 58   | 0.354   |
| 3                | 82  | 648  | 0.570   | 914 | 120  | 0.877   | 914 | 121  | 0.748   |
| **Pleomorphism**|     |      |         |     |      |         |     |      |         |
| 1                | 2   | 10   | 0.844   | 21  | 1    | 0.000   | 20  | 1    | 0.594   |
| 2                | 43  | 265  | 0.233   | 447 | 50   | 0.312   | 439 | 59   | 0.360   |
| 3                | 78  | 739  | 0.650   | 968 | 152  | 0.938   | 987 | 135  | 0.826   |
| **Mitosis**      |     |      |         |     |      |         |     |      |         |
| 1                | 63  | 454  | 0.233   | 720 | 99   | 0.012   | 719 | 103  | 0.050   |
| 2                | 18  | 208  | 0.183   | 280 | 25   | 0.151   | 281 | 24   | 0.151   |
| 3                | 42  | 351  | 0.309   | 434 | 78   | 0.484   | 444 | 68   | 0.416   |
| **Vascular invasion**| | |         | | | | | | |
| Definite         | 50  | 297  | 0.012   | 415 | 64   | 0.461   | 426 | 53   | 0.614   |
| No/probable      | 75  | 726  | 0.562   | 1030| 141  | 0.850   | 1033| 141  | 0.850   |
| **Stage**        |     |      |         |     |      |         |     |      |         |
| 1                | 74  | 649  | 0.278   | 926 | 118  | 0.050   | 931 | 113  | 0.082   |
| 2                | 32  | 271  | 0.237   | 376 | 70   | 0.424   | 383 | 66   | 0.406   |
| 3                | 18  | 101  | 0.887   | 148 | 17   | 0.104   | 148 | 16   | 0.104   |
| **Nottingham Prognostic Index** | | | | | | | | | |
| Good             | 37  | 328  | 0.303   | 515 | 63   | 0.315   | 516 | 62   | 0.597   |
| Medium           | 60  | 526  | 0.460   | 704 | 111  | 0.673   | 716 | 102  | 0.629   |
| Poor             | 27  | 166  | 0.450   | 223 | 31   | 0.194   | 223 | 31   | 0.194   |
| **ER status**    |     |      |         |     |      |         |     |      |         |
| Negative         | 21  | 215  | 0.273   | 274 | 43   | 0.507   | 281 | 36   | 0.797   |
| Positive         | 104 | 809  | 0.704   | 1174| 162  | 0.987   | 1180| 159  | 0.967   |
| **PR status**    |     |      |         |     |      |         |     |      |         |
| Negative         | 52  | 414  | 0.831   | 579 | 82   | 0.865   | 586 | 75   | 0.597   |
| Positive         | 66  | 548  | 0.507   | 784 | 114  | 0.733   | 790 | 110  | 0.733   |
| **HER2 status**  |     |      |         |     |      |         |     |      |         |
| Negative         | 105 | 867  | 0.980   | 1249| 176  | 0.529   | 1262| 166  | 0.251   |
| Positive         | 11  | 90   | 0.848   | 108 | 15   | 0.124   | 107 | 19   | 0.134   |

Note: The P values are resultant from Pearson’s chi-squared test of association, and significant values (P < .05) are highlighted in bold.
compared with DARPP-32 and Cdk5 which has been described previously.15,16

3 | RESULTS

3.1 | PKA and PP1 protein staining and frequency and correlation of expression

The majority of PKA expression was cytoplasmic with weak to strong staining intensity observed in tumour cells; representative staining is shown in Figure 1B,C. The median PKA H-score was 160 and ranged from 0 to 290; X-tile computed a H-score cut-point of 90, with 89.0% (1032/1159) cases demonstrating high expression. PP1 expression was observed in both the cytoplasm and the nucleus; representative staining is shown in Figure 1D,E. Cytoplasmic PKA expression had a median H-score of 0 and ranged from 0 to 160. X-tile computed a H-score cut-point of 25, with 12.6% (187/1488) cases demonstrating high expression. Nuclear PKA expression had a median H-score of 0 and ranged from 0 to 100. X-tile computed a H-score cut-point of 20, with 11.9% (178/1491) cases demonstrating high expression. Representative PKA and PP1 protein expression is demonstrated in Figure 1A.

Correlations between the expression of PKA and PP1 together with DARPP-32 and Cdk5 were assessed. Many of the combinations were statistically significant; however, they were of weak biological significance (Figure 1E). PKA expression was significantly correlated with cytoplasmic (\(P = .012, R^2 = .077\)) and nuclear (\(P = .047, R^2 = .061\)) PP1 expression. PKA expression was significantly correlated with cytoplasmic (\(P = .030, R^2 = .066\)) and nuclear (\(P = .014, R^2 = .075\)) DARPP-32 expression. PKA expression was significantly correlated with cytoplasmic (\(P < .001, R^2 = .169\)) and nuclear (\(P < .001, R^2 = .128\)) Cdk5 expression. Cytoplasmic PKA expression was not significantly correlated with cytoplasmic (\(P = .410, R^2 = .021\)) and nuclear (\(P = .991, R^2 = .000\)) DARPP-32 expression, but was significantly correlated with cytoplasmic (\(P < .001, R^2 = .154\)) and nuclear (\(P = .025, R^2 = .070\)) Cdk5 expression.

3.2 | Relationship between PKA and PP1 protein expression and clinicopathological criteria

Low expression of PKA was significantly associated with the presence of lymphovascular invasion (LVI) (\(\chi^2 = 6.353, df = 1, P = .012\)). PKA expression was not associated with any other clinicopathological variables (Table 1).

Low cytoplasmic PKA expression was associated with pleomorphism (\(\chi^2 = 6.918, df = 2, P = .031\)) and mitosis (\(\chi^2 = 8.849, df = 2, P = .012\)). Low nuclear PKA expression was associated with older patient age (\(\chi^2 = 4.112, df = 1, P = .043\)). Nuclear and cytoplasmic PKA expression was not associated with any other clinicopathological variables (Table 1).

3.3 | Association between PKA and PP1 protein expression and survival

Low PKA expression was significantly associated with adverse survival of breast cancer patients (\(P = .040\)) (Figure 2A). Ten-year survival of breast cancer patients with high expression of PKA was 82.3% (95% confidence interval (CI) = 0.768-0.848) and low expression of PKA was 77.6% (95% CI = 0.675-0.835). Expression of PKA did not remain associated with survival when potentially confounding factors of tumour size, grade, nodal stage, ER status, PR status, HER2 status, and LVI status were included in multivariate Cox regression analysis (\(P = .010\); hazard ratio (HR)=0.768; 95% CI = 0.513-1.151) (all with individual log-rank statistics of \(P < .001\)). Interestingly, a stronger association was observed between low levels of PKA expression and adverse survival in ER-positive breast cancer patients (\(P = .003\)) (Figure 2B).

Cytoplasmic and nuclear PP1 protein expression was not associated with survival of breast cancer patients (\(P = .217\) and \(P = .428\)) (Figure 2C,D).

Associations between combined PKA, PP1, DARPP-32 and Cdk5 expression and breast cancer-specific survival were assessed. The combination of low PKA and low Cdk5 expression (\(P = .006\); Figure 3B), low PKA and low DARPP-32 (\(P = .001\); Figure 3C) and combination of low PKA and low Cdk5 (\(P = .010\); Figure 3D) showed significant association with shorter survival. However, the combined expression of PKA and DARPP-32 was not associated with breast cancer-specific survival (\(P = .139\)) (Figure 3A).

3.4 | PKA and PP1 mRNA expression in the METABRIC cohort

PKA and PP1 mRNA expression was assessed for association with patient survival in the METABRIC cohort using probe-level information. Probe-level information was used so that correlations with PPP1R1B variants could be assessed. PPP1R1B probe 1 (ILMN_1690096) is located within a coding area that corresponds to the N-terminal region of DARPP-32; PPP1R1B probe 2 (ILMN_1759012) and PPP1R1B probe 3 (ILMN_2304495) were both located in untranslated regions (5′ and 3′, respectively). DARPP-32 mRNA would align with probe 1 and probe 3; t-DARPP mRNA would align with probe 2 and probe 3. PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B, PRKAR2A and PRKAR2B were assessed for PKA and PPP1CA, PPP1CB and PPP1CC were assessed for PP1; heat map visualization of expression and correlation between expression is shown in Figure 4A,B.

Table 2 shows associations between probe-level information and patient survival in the METABRIC cohort using the Cox (proportional hazards) regression analysis. PRKACG, PRKAR1B and PPP1CA were associated with patient survival. One of five probes for PRKACB, one of three probes for PRKAR1A and one of two probes for PPP1CB were associated with patient survival.
This study investigated the expression and co-expression of four important signalling proteins in breast cancer and assessed their prognostic and clinical significance. We provide evidence that low expression of PKA is significantly associated with adverse survival of breast cancer patients in a large cohort of breast cancer patients; interestingly, this relationship was stronger in ER-positive breast cancer patients. The ER relationship is interesting, as we have made similar observations with DARPP-32 expression as part of previous studies. PP1 expression was not associated with patient survival. Previous studies have linked DARPP-32 and HER2-positive breast cancer; our current findings provide further evidence that the DARPP-32 signalling nexus plays a role in breast cancer subgroups, in particular, in ER-positive disease.

The function of both PKA and PP1 can be inhibited by DARPP-32 dependent upon its phosphorylation status. DARPP-32 can be phosphorylated by PKA on threonine 34 to allow PP1 inhibition or by Cdk5 on threonine 75 to allow inhibition of PKA. Our findings demonstrate that PKA expression was significantly correlated with DARPP-32 and Cdk5 expression (both determined in previous studies). Our findings also demonstrate that PP1 expression was significantly correlated with previously determined Cdk5 expression, but not DARPP-32 expression. It is important to note that this study assessed the expression level of PKA and PP1 protein and mRNA and inference on cellular activity cannot be made. PP1 expression was assessed in both the cytoplasm and the nucleus, whereas PKA was only observed in the cytoplasm. Neither PP1 nuclear or cytoplasmic expression was associated with patient survival; however, different associations were observed with clinicopathological variables. Cytoplasmic PKA was associated with pleomorphism and mitosis, indicating an association with altered cell growth, whereas nuclear PP1 was associated with patient age, studies have indicated differential subcellular localization.

In addition to protein expression, mRNA expression of PKA and PP1 subunits was assessed, including PRKACA, PRKACB, PRKACG, PRKAR1A, PRKAR1B, PRKAR2A and PRKAR2B, for PKA and PPP1CA, PPP1CB and PPP1CC for PP1. Probe-level information was assessed so that correlations could be made with represented PPP1R1B variants in the data set. Expression of the three PPP1R1B probes were closely related; however, no strong biologically relevant association was observed between expression of the PPP1R1B probes and other probes assessed in this study. PRKACG, PRKAR1B and PPP1CA were the most strongly and reproducibly associated with breast cancer-specific survival. There were other significant associations between specific probes and survival; one of five probes of PRKACB, one of three probes for PRKAR1A and one of two probes for PPP1CB. PRKACB, PRKAR1A and PPP1CB have multiple splice variants, and the observation that not all probes are associated with survival, may indicate that certain transcripts are more important in breast cancer and warrants further investigation.

**FIGURE 2** Kaplan-Meier analysis of PKA (A) and PKA expression in oestrogen receptor-positive breast cancer (B) and cytoplasmic (C) and nuclear (D) PP1 expression where the impact of low (grey line) and high (black line) expression is shown.
In breast cancer, low PRKAR1A expression in combination with high SRC expression has been shown to be associated with basal-like and HER2-positive breast cancer associated with poor survival, and in HER2-resistant breast cancer, down-regulation of PRKAR2A and PRKAR2B has been observed, in combination with an observed increase with PPP1R1B. Our findings suggest that PRKAR1B and PRKACG were associated with disease-specific survival of the total patient cohort.

Our findings suggest that PPP1CA, PRKACG and PRKAR1B are associated with breast cancer–specific survival. Previously published studies have indicated a role for PPP1CA in cancer,26,27 in breast cancer, PPP1CA may play a role in cancer stem cell populations.28 Although a role for PRKACG and PRKAR1B in breast cancer has not been described, PRKACG has been shown to act as a RUNX1-mutation associated hub gene in acute myeloid leukaemia29 and single nucleotide polymorphisms of PRKAR1B are associated with inferior survival of advanced renal cell cancer patients.30

In previous studies, we demonstrated that low DARPP-32 and Cdk5 expression is associated with adverse survival of breast cancer patients.15,16 We hypothesized that a reduction in DARPP-32 and an increase in t-DARPP in breast cancer result in a concomitant alteration of PKA and PP1 signalling. In this study, we explored associations between PKA, PP1, DARPP-32 and Cdk5 expression and breast cancer–specific survival. The combination of PKA and Cdk5 expression was significantly associated with survival as was the combined expression of PP1 and DARPP-32 and the combined expression of PP1 and Cdk5. In patients with high expression of DARPP-32, low expression of PP1 was associated with adverse survival when compared to high expression in the same group. In patients with high expression of Cdk5, high expression of PKA was associated with adverse survival when compared with low expression in the same subgroup; low expression of PP1 was significantly associated with adverse survival when compared with high expression in the same subgroup. These findings warrant further functional investigation of the DARPP-32 signalling nexus in breast cancer, with a particular focus in ER-positive disease.

5 | CONCLUSION

Low PKA expression was significantly associated with adverse survival of breast cancer patients in a large cohort of breast cancer
patients; interestingly, this relationship was stronger in ER-positive breast cancer patients. PP1 protein expression was not associated with patient survival. PKA and PP1 subunit mRNA expression was also assessed; PPP1CA, PRKACG and PRKAR1B were associated with breast cancer-specific survival. PKA expression and PP1 expression are of significant interest in cancer as they are involved in a wide array of cellular processes and may play an important role in patient outcome.

ACKNOWLEDGEMENTS
We thank the Nottingham Health Science Biobank and Breast Cancer Now for the provision of tissue samples.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

AUTHOR CONTRIBUTION
Behnaz Saidy: Data curation (equal); formal analysis (equal); investigation (equal); writing – review and editing (equal). Shreeya Kotecha: Data curation (equal); investigation (equal); writing – review and editing (equal). Anna Butler: Data curation (equal); investigation (equal); writing – review and editing (equal). Emad A. Rakha: Resources (equal); writing – review and editing (equal). Ian O. Ellis: Resources (equal); writing – review and editing (equal). Andrew R. Green: Resources (equal); writing – review and editing (equal). Stewart G. Martin: Project administration (equal); resources (equal); supervision (equal); writing – review and editing (equal). Sarah J. Storr: Conceptualization (lead); data curation

| Gene     | Probe          | P value | Hazard ratio | 95% confidence interval |
|----------|----------------|---------|--------------|-------------------------|
| PRKACA   | ILMN_1786195   | .685    | 0.892        | 0.513-1.552             |
|          | ILMN_2395314   | .171    | 1.411        | 0.862-2.311             |
| PRKACB   | ILMN_1690314   | .021    | 0.451        | 0.230-0.885             |
|          | ILMN_1759922   | .189    | 1.576        | 0.800-3.103             |
|          | ILMN_1771523   | .434    | 0.871        | 0.556-1.364             |
|          | ILMN_2278112   | .546    | 0.871        | 0.575-1.334             |
|          | ILMN_2374234   | .161    | 0.924        | 0.827-1.032             |
| PRKACG   | ILMN_1808368   | .045    | 1.616        | 1.011-2.582             |
| PRKAR1A  | ILMN_1738632   | .065    | 0.898        | 0.801-1.007             |
|          | ILMN_2277077   | .003    | 0.395        | 0.215-0.724             |
|          | ILMN_2389590   | .146    | 0.953        | 0.893-1.017             |
| PRKAR1B  | ILMN_1674390   | .001    | 1.612        | 1.205-2.156             |
| PRKAR2A  | ILMN_1681888   | .347    | 0.863        | 0.635-1.173             |
| PRKAR2B  | ILMN_1684850   | .465    | 0.797        | 0.433-1.467             |
| PPP1CA   | ILMN_1695827   | .017    | 1.215        | 1.035-1.426             |
|          | ILMN_2377980   | .001    | 1.732        | 1.416-2.118             |
| PPP1CB   | ILMN_2405018   | .003    | 0.772        | 0.651-0.916             |
|          | ILMN_2405023   | .208    | 0.779        | 0.527-1.150             |
| PPP1CC   | ILMN_1701855   | .605    | 0.977        | 0.758-1.175             |

Note: P values, hazard ratio and 95% confidence interval around the hazard ratio are shown. Significant results are highlighted in bold.
ETHICAL APPROVAL

Ethical approval was granted by Nottingham Research Ethics Committee 2, under the title ‘Development of a molecular genetic classification of breast cancer’ (C202313). METABRIC samples were collected by five centres in the UK and Canada and were acquired with appropriate consent from the respective institutional review boards. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All samples collected from Nottingham used in this study were pseudo-anonymized; those collected prior to 2006 did not require informed patient consent under the Human Tissue Act; after 2006, informed consent was obtained from all individual participants included in the study.

DATA AVAILABILITY STATEMENT

The METABRIC data set is publically available at https://www.ebi.ac.uk/ega/studies/EGAS000000000098. Immunohistochemistry data sets analysed during the current study are available from the corresponding author on reasonable request.

ORCID

Sarah J. Storr https://orcid.org/0000-0002-4103-6048

REFERENCES

1. Michalides R, Griekspoor A, Balkenende A, et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell. 2004;5:597-605.
2. de Leeuw R, Flach K, Bentin Toaldo C, et al. PKA phosphorylation redirects ERalpha to promoters of a unique gene set to induce tamoxifen resistance. Oncogene. 2013;32:3543-3545.
3. Beristain AG, Molyneux S, Joshi PA, et al. PKA signaling drives mammalian tumorigenesis through Src. Oncogene. 2015;34:1160-1173.
4. Gu L, Lau SK, Loera S, Somlo G, Kane SE. Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines. Clin Cancer Res. 2009;15:7196-7206.
5. Moura M, Conde C. Phosphatases in mitosis: roles and regulation. Bioluminesc. 2019;9(2):55.
6. Ruvolo PP. Role of protein phosphatases in the cancer microenvironment. Biochim Biophys Acta Mol Cell Res. 2019;1866(1):144-152.
7. Martin-Granados C, Prescott AR, Van Dessel N, et al. A role for PP1/NIPPP1 in steering migration of human cancer cells. PLoS One. 2012;7:e40769.
8. Winter SL, Bosnoyan-Collins L, Pinnaduwage D, Andrilis IL. The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors. BMC Cancer. 2007;7:85.
9. Walaas S I, Aswad D W, Greengard P. A dopamine- and cyclic AMP-regulated phosphoprotein enriched in dopamine-innervated brain regions. Nature. 1983;301:69-71.
10. Hemmings HC Jr, Greengard P, Tung HY, Cohen P. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature. 1984;310:503-505.
11. Bibb JA, Snyder GL, Nishi A, et al. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature. 1999;402:669-671.
12. El-Rifai W, Smith MF Jr, Li G, et al. Gastric cancers overexpress DARPP-32 and a novel isoform, t-DARPP. Cancer Res. 2002;62:4061-4064.
13. Theile D, Geng S, Denny EC, Momand J, Kane SE. t-Darpp stimulates protein kinase A activity by forming a complex with its RI regulatory subunit. Cell Signal. 2017;40:53-61.
14. Avanes A, Lenz G, Momand J. Darpp-32 and t-Darpp protein products of PPP1R1B: old dogs with new tricks. Biochem Pharmacol. 2019;160:71-79.
15. Martin SG, Zhang S, Yang S, Saidy B, Deen S, Storr SJ. Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32), protein phosphatase-1 and cyclin-dependent kinase 5 expression in ovarian cancer. J Cell Mol Med. 2020;24(16):9165-9175.
16. Saidy B, Rakha EA, Green AR, Ellis IO, Martin SG, Storr SJ. Retrospective assessment of cyclin-dependent kinase 5 mRNA and protein expression and its association with patient survival in breast cancer. J Cell Mol Med. 2020;24:6263-6271.
17. Lenz G, Hamilton A, Geng S, et al. t-Darpp activates IGF-1R signaling to regulate glucose metabolism in trastuzumab-resistant breast cancer cells. Clin Cancer Res. 2018;24:1216-1226.
18. Zhu S, Soutto M, Chen Z, et al. Activation of IGFR1 by DARPP-32 promotes STAT3 signaling in gastric cancer cells. Oncogene. 2019;38:5805-5816.
19. Alam SK, Wang L, Ren Y, et al. ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumour cell proliferation. Br J Cancer. 2020;123:819-832.
20. Alam SK, Astone M, Liu P, et al. DARPP-32 and t-DARPP promote non-small cell lung cancer growth through regulation of IKKalpha-dependent cell migration. Commun Biol. 2018;1:43.
21. Tiwari A, Tashiro K, Dixit A, et al. Loss of HIF1A from pancreatic cancer cells increases expression of PPP1R1B and degradation of p53 to promote invasion and metastasis. Gastroenterology. 2020;159:1882-1897.e5
22. Curtis C, Shah SP, Chin S-F, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346-352.
23. Camp RL, Doolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252-7259.
24. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Statistics Subcommittee of the NCIEWGCD. REporting recommen-dations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93:387-391.
25. Andreassen PR, Lacroix FB, Villa-Moruzzi E, Margolis RL. Differential subcellular localization of protein phosphatase-1 alpha, gamma1, and delta isoforms during both interphase and mitosis in mammalian cells. J Cell Biol. 1998;141:1207-1215.
26. Sun H, Ou B, Zhao S, et al. USP11 promotes growth and metastasis of colorectal cancer via PPP1CA-mediated activation of ERK/MAPK signaling pathway. EBioMedicine. 2019;48:236-247.
27. Verdugo-Sivianes EM, Navas L, Molina-Pinelo S, et al. Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancer. Oncotarget. 2017;8:105196-105210.
29. Zhu F, Huang R, Li J, Liao X, Huang Y, Lai Y. Identification of key genes and pathways associated with RUNX1 mutations in acute myeloid leukemia using bioinformatics analysis. Med Sci Monit. 2018;24:7100-7108.

30. Garrigos C, Espinosa M, Salinas A, et al. Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma. Oncotarget. 2017;8:106551-106564.

How to cite this article: Saidy B, Kotecha S, Butler A, et al. PP1, PKA and DARPP-32 in breast cancer: A retrospective assessment of protein and mRNA expression. J Cell Mol Med. 2021;25:5015–5024. https://doi.org/10.1111/jcmm.16447